Table 2. Cryoglobulin types and levels regarding delay after Chikungunya infection onset, at Laveran Military hospital, Marseille, France.
| Delay | No cryoglobulin Prevalence (%) | Type IIa Prevalence (%) [median level] | Type II–IIIb Prevalence (%) [median level] | Type III Prevalence (%) [median level] | All typesc Prevalence (%) [median level] |
| 0–30 days | 2/16 (12.5%) | 10/16 (62.5%) [14.5 mg.L−1] | 2/16 (12.5%) [2.7 mg.L−1] | 2/16 (12.5%) [6.8 mg.L−1] | 14/16 (87.5%) [7.7 mg.L−1] |
| 31–90 days | 3/28 (10.7%) | 14/28 (50.0%) [10.1 mg.L−1] | 7/28 (25.0%) [25.2 mg.L−1] | 4/28 (14.3%) [35.9 mg.L−1] | 25/28 (89.3%) [10.4 mg.L−1] |
| 91–180 days | 10/27 (37.0%) | 10/27 (37.0%) [6.54 mg.L−1] | 7/27 (25.9%) [26.2 mg.L−1] | 0/27 (0%) | 17/27 (63.0%) [11.7 mg.L−1] |
| 181–747 days | 20/47 (42.6%) | 17/47 (36.2%) [3.1 mg.L−1] | 9/47 (19.1%) [4.1 mg.L−1] | 1/47 (2.1%) [21.6 mg.L−1] | 27/47 (57.4%) [3.7 mg.L−1] |
a
p = 0.008.
b
p = 0.04.
c
p = 0.002 (Kruskall-Wallis test for distribution between the different delays).